New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
07:40 EDTCBSTCubist announces EMA acceptance of Tedizolid MAA for review
Cubist Pharmaceuticals announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application, or MAA, for its investigational antibiotic tedizolid phosphate. Cubist is seeking approval of tedizolid for the treatment of complicated skin and soft tissue infections, with a decision from the European Commission expected during the first half of 2015. Tedizolid is a once daily oxazolidinone being developed for both intravenous and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria, including those caused by methicillin-resistant Staphylococcus aureus. The MAA submission is based on positive data from two global Phase 3 clinical studies of tedizolid, which met the primary and secondary endpoints defined by the EMA and U.S. Food and Drug Administration.
News For CBST From The Last 14 Days
Check below for free stories on CBST the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
17:13 EDTCBSTCubist sees FY14 revenue toward low end of previous range
Subscribe for More Information
16:01 EDTCBSTCubist reports Q2 EPS 23c, may not compare to consensus 2c
Subscribe for More Information
July 14, 2014
05:51 EDTCBSTAchaogen appoints Dr. Ian Friedland as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use